Quin Wills (L) and Jack O’Meara, Ochre Bio

A liv­er dis­ease up­start with some glob­al con­nec­tions and a new R&D strat­e­gy reaps a $30M launch round

LON­DON — Back when Jack O’Meara and Quin Wills were ini­tial­ly set­ting up Ochre Bio, they jumped from their home base in the UK to the US pri­mar­i­ly so they could es­tab­lish a syn­di­cate of in­vestors who could fund their start­up as they be­gan to ex­plore new RNA ther­a­pies for liv­er dis­eases.

And the strat­e­gy is work­ing fine.

Along the way, they got to know a lot of the peo­ple at Y Com­bi­na­tor, set­ting up a $10 mil­lion seed round last year that put them on track to the $30 mil­lion launch round the CEO/CSO founder team is un­veil­ing to­day. Their back­ers now in­clude In­tel­lia founder Nes­san Berming­ham at Khosla as well as Al­ice Zhang, the CEO at Verge Ge­nomics who is putting some of her own mon­ey be­hind Ochre.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.